Edgewise Therapeutics Stock
Edgewise Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Kevin Koch
- Employees
- 127
- Market cap
- $4 B
- IPO
- 26/03/2021
Edgewise Therapeutics, Inc. is a healthcare company headquartered in Boulder, US, which specializes in the development of small-molecule treatments for a range of musculoskeletal disorders. Founded in 2017 and led by CEO Kevin Koch, the firm maintains a pipeline of precision medicine candidates designed to modulate…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Edgewise Therapeutics stock: price history
1D
-2.6%
1W
-4.8%
1M
-18.2%
6M
+8.0%
YTD
+49.8%
1Y
+142.8%
2Y
+6.2%
5Y
+109.6%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~1% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Edgewise Therapeutics
Analyst assessment of Edgewise Therapeutics
PRICE TARGET LOW
US$36.00
CONSENSUS
US$53.10
MEDIAN
US$52.00
PRICE TARGET HIGH
US$66.00
0
STRONG BUY
9
BUY
2
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 21/09/2026
Edgewise Therapeutics stock metrics
P/E
-20.1
P/B
8.94
EV/EBITDA
-20.18
RETURN ON EQUITY
-12.8%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
76.1%
FLOAT SHARES
81,917,717
AVG. DAILY VOLUME (30D)
1,604,967
Insider transactions (SEC)
Fox Jonathan C
Donovan Joanne M.
Derakhshan Behrad
Derakhshan Behrad
Derakhshan Behrad
Institutional holders
Comparable stocks
Frequently asked questions about Edgewise Therapeutics stock
What does Edgewise Therapeutics do?
Edgewise Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Kevin Koch, the company employs around 127 people.
The IPO was on 26/03/2021; the stock trades on NASDAQ under the ticker EWTX.
What do analysts say about Edgewise Therapeutics stock?
11 analysts rate the stock, the consensus is Buy (as of 21/09/2026).
The average price target is US$53.10, ranging from US$36.00 to US$66.00, with a median of US$52.00.
This is an external assessment, not a statement by Market Jury.
When does Edgewise Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 1% stronger than usual.
Does Edgewise Therapeutics pay a dividend?
No, Edgewise Therapeutics currently does not pay a dividend.
Which stocks are comparable to Edgewise Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Edgewise Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Edgewise Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.